AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Radiopharm Theranostics Limited American Depositary Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01PT2ZVT9
1.01▲ 0.06 (6.32%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.95
Day's Range
1.00 – 1.07
52-Week Range
0.90 – 16.25
Volume
32.0K
Avg Volume
57.3K
Share Statistics
Shares Outstanding
Employees
14
Exchange
XNAS
Listed
2024-11-27
Share count as of June 30, 2026

Radiopharm Theranostics Limited American Depositary Shares (RADX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Radiopharm Theranostics Limited American Depositary Shares (RADX)
What is Radiopharm Theranostics Limited American Depositary Shares's Market Cap?
Radiopharm Theranostics Limited American Depositary Shares's Market Cap is $3.6B, based on as-reported figures from SEC (XBRL) filings.
What is Radiopharm Theranostics Limited American Depositary Shares's Enterprise Value?
Radiopharm Theranostics Limited American Depositary Shares's Enterprise Value is $3.6B, based on as-reported figures from SEC (XBRL) filings.
What is Radiopharm Theranostics Limited American Depositary Shares's Price / Sales?
Radiopharm Theranostics Limited American Depositary Shares's Price / Sales is 985.2×, based on as-reported figures from SEC (XBRL) filings.
What is Radiopharm Theranostics Limited American Depositary Shares's EV / Revenue?
Radiopharm Theranostics Limited American Depositary Shares's EV / Revenue is 977.2×, based on as-reported figures from SEC (XBRL) filings.
What is Radiopharm Theranostics Limited American Depositary Shares's Revenue (TTM)?
Radiopharm Theranostics Limited American Depositary Shares's Revenue (TTM) is $3.6M, based on as-reported figures from SEC (XBRL) filings.
What is Radiopharm Theranostics Limited American Depositary Shares's Net Income (TTM)?
Radiopharm Theranostics Limited American Depositary Shares's Net Income (TTM) is -$38.3M, based on as-reported figures from SEC (XBRL) filings.
What is Radiopharm Theranostics Limited American Depositary Shares's Diluted EPS (TTM)?
Radiopharm Theranostics Limited American Depositary Shares's Diluted EPS (TTM) is -0.01, based on as-reported figures from SEC (XBRL) filings.
What is Radiopharm Theranostics Limited American Depositary Shares's Net Debt?
Radiopharm Theranostics Limited American Depositary Shares's Net Debt is -$29.1M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RADXAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Jun 30, 2025Jun 30, 2024Jun 30, 2023
Revenue from contracts with customers
Cost of sales
Gross Profit
Other income
Other losses
General and administrative expenses
Research and development expenses
Share-based payments expenses
Gain/(loss) on movement in contingent consideration
Operating loss
Finance expenses
Loss before income tax
Income tax expense
Loss for the year
Other comprehensive income/(loss)
Exchange differences on translation of foreign operations
Total comprehensive loss for the year
Total comprehensive loss for the year is attributable to:
Owners of Radiopharm Theranostics Limited
Non-controlling interests
Total comprehensive loss for the year
Loss per share for loss attributable to the ordinary equity holders of the group:
Basic loss per share (in Dollars per share)
Diluted loss per share (in Dollars per share)